ArticleBiotechnology journal2026
Engineering a Membrane-Anchored CreER Recombinase With Reduced Basal Activity for In Vitro Recombination.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The CreER-loxP system is widely utilized for genetic cell lineage tracing and conditional gene function analysis. However, issues have arisen concerning the unintended labeling of nontarget cell populations, which complicate experimental data analysis and interpretation. In this study, we constructed an engineered CreER-loxP system in which a membrane‑localization motif was fused to the C‑terminus of Cre, thereby anchoring the fusion protein to the cell membrane and minimizing its spontaneous leakage into the nucleus. This membrane‑tethered CreER-loxP (mCreER-loxP) system substantially reduced nonspecific labeling in the absence of tamoxifen. Upon tamoxifen induction, the membrane‑localized Cre dissociated from the membrane and translocated into the nucleus, maintaining comparable recombination efficiency with the conventional CreER-loxP system. Notably, the membrane‑tethering design demonstrates enhanced performance under conditions of high expression levels and extended duration in vitro, even within the more stringent ERCreER-loxP labeling framework. Furthermore, mCreER exhibited reduced cytotoxicity relative to standard CreER. Collectively, these results indicate that the mCreER-loxP system provides improved temporal and spatial precision for applications in cell lineage tracing and genetic engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.